These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38393391)

  • 1. Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors.
    Stutheit-Zhao EY; Sanz-Garcia E; Liu ZA; Wong D; Marsh K; Abdul Razak AR; Spreafico A; Bedard PL; Hansen AR; Lheureux S; Torti D; Lam B; Yang SYC; Burgener J; Luo P; Zeng Y; Cheng N; Awadalla P; Bratman SV; Ohashi PS; Pugh TJ; Siu LL
    Cancer Discov; 2024 Jun; 14(6):1048-1063. PubMed ID: 38393391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab.
    Hernando-Calvo A; Yang SYC; Vila-Casadesús M; Han M; Liu ZA; Berman AHK; Spreafico A; Razak AA; Lheureux S; Hansen AR; Lo Giacco D; Abbas-Aghababazadeh F; Matito J; Haibe-Kains B; Pugh TJ; Bratman SV; Aleshin A; Berche R; Saavedra O; Garralda E; Elston S; Siu LL; Ohashi PS; Vivancos A; Bedard PL
    JCO Precis Oncol; 2024 Aug; 8():e2400100. PubMed ID: 39178369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.
    Burgener JM; Zou J; Zhao Z; Zheng Y; Shen SY; Huang SH; Keshavarzi S; Xu W; Liu FF; Liu G; Waldron JN; Weinreb I; Spreafico A; Siu LL; de Almeida JR; Goldstein DP; Hoffman MM; De Carvalho DD; Bratman SV
    Clin Cancer Res; 2021 Aug; 27(15):4230-4244. PubMed ID: 34158359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial.
    Powles T; Chang YH; Yamamoto Y; Munoz J; Reyes-Cosmelli F; Peer A; Cohen G; Yu EY; Lorch A; Bavle A; Homet Moreno B; Markensohn J; Edmondson M; Chen C; Cristescu R; Peña C; Lunceford J; Gunduz S
    Nat Med; 2024 Sep; 30(9):2508-2516. PubMed ID: 38823511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
    Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
    J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab.
    Watson GA; Sanz-Garcia E; Zhang WJ; Liu ZA; Yang SC; Wang B; Liu S; Kubli S; Berman H; Pfister T; Genta S; Spreafico A; Hansen AR; Bedard PL; Lheureux S; Abdul Razak A; Cescon D; Butler MO; Xu W; Mak TW; Siu LL; Chen E
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.
    Bratman SV; Yang SYC; Iafolla MAJ; Liu Z; Hansen AR; Bedard PL; Lheureux S; Spreafico A; Razak AA; Shchegrova S; Louie M; Billings P; Zimmermann B; Sethi H; Aleshin A; Torti D; Marsh K; Eagles J; Cirlan I; Hanna Y; Clouthier DL; Lien SC; Ohashi PS; Xu W; Siu LL; Pugh TJ
    Nat Cancer; 2020 Sep; 1(9):873-881. PubMed ID: 35121950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
    Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.
    Duruisseaux M; Martínez-Cardús A; Calleja-Cervantes ME; Moran S; Castro de Moura M; Davalos V; Piñeyro D; Sanchez-Cespedes M; Girard N; Brevet M; Giroux-Leprieur E; Dumenil C; Pradotto M; Bironzo P; Capelletto E; Novello S; Cortot A; Copin MC; Karachaliou N; Gonzalez-Cao M; Peralta S; Montuenga LM; Gil-Bazo I; Baraibar I; Lozano MD; Varela M; Ruffinelli JC; Palmero R; Nadal E; Moran T; Perez L; Ramos I; Xiao Q; Fernandez AF; Fraga MF; Gut M; Gut I; Teixidó C; Vilariño N; Prat A; Reguart N; Benito A; Garrido P; Barragan I; Emile JF; Rosell R; Brambilla E; Esteller M
    Lancet Respir Med; 2018 Oct; 6(10):771-781. PubMed ID: 30100403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.
    Iijima Y; Hirotsu Y; Amemiya K; Ooka Y; Mochizuki H; Oyama T; Nakagomi T; Uchida Y; Kobayashi Y; Tsutsui T; Kakizaki Y; Goto T; Miyashita Y; Omata M
    Eur J Cancer; 2017 Nov; 86():349-357. PubMed ID: 29078173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity.
    Cindy Yang SY; Lien SC; Wang BX; Clouthier DL; Hanna Y; Cirlan I; Zhu K; Bruce JP; El Ghamrasni S; Iafolla MAJ; Oliva M; Hansen AR; Spreafico A; Bedard PL; Lheureux S; Razak A; Speers V; Berman HK; Aleshin A; Haibe-Kains B; Brooks DG; McGaha TL; Butler MO; Bratman SV; Ohashi PS; Siu LL; Pugh TJ
    Nat Commun; 2021 Aug; 12(1):5137. PubMed ID: 34446728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy.
    Thompson JC; Carpenter EL; Silva BA; Rosenstein J; Chien AL; Quinn K; Espenschied CR; Mak A; Kiedrowski LA; Lefterova M; Nagy RJ; Katz SI; Yee SS; Black TA; Singh AP; Ciunci CA; Bauml JM; Cohen RB; Langer CJ; Aggarwal C
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34095713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-cancer landscape of abnormal ctDNA methylation across human tumors.
    Bai Y; Qu D; Lu D; Li Y; Zhao N; Cui G; Li X; Sun X; Sun H; Zhao L; Li Q; Zhang Q; Han T; Wang S; Yang Y
    Cancer Genet; 2022 Nov; 268-269():37-45. PubMed ID: 36152512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor DNA methylation: a promising clinical tool for cancer diagnosis and management.
    Wang B; Wang M; Lin Y; Zhao J; Gu H; Li X
    Clin Chem Lab Med; 2024 Oct; 62(11):2111-2127. PubMed ID: 38443752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
    Ashida A; Sakaizawa K; Uhara H; Okuyama R
    Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC.
    Hellmann MD; Nabet BY; Rizvi H; Chaudhuri AA; Wells DK; Dunphy MPS; Chabon JJ; Liu CL; Hui AB; Arbour KC; Luo J; Preeshagul IR; Moding EJ; Almanza D; Bonilla RF; Sauter JL; Choi H; Tenet M; Abu-Akeel M; Plodkowski AJ; Perez Johnston R; Yoo CH; Ko RB; Stehr H; Gojenola L; Wakelee HA; Padda SK; Neal JW; Chaft JE; Kris MG; Rudin CM; Merghoub T; Li BT; Alizadeh AA; Diehn M
    Clin Cancer Res; 2020 Jun; 26(12):2849-2858. PubMed ID: 32046999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).
    Clouthier DL; Lien SC; Yang SYC; Nguyen LT; Manem VSK; Gray D; Ryczko M; Razak ARA; Lewin J; Lheureux S; Colombo I; Bedard PL; Cescon D; Spreafico A; Butler MO; Hansen AR; Jang RW; Ghai S; Weinreb I; Sotov V; Gadalla R; Noamani B; Guo M; Elston S; Giesler A; Hakgor S; Jiang H; McGaha T; Brooks DG; Haibe-Kains B; Pugh TJ; Ohashi PS; Siu LL
    J Immunother Cancer; 2019 Mar; 7(1):72. PubMed ID: 30867072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.
    Hrebien S; Citi V; Garcia-Murillas I; Cutts R; Fenwick K; Kozarewa I; McEwen R; Ratnayake J; Maudsley R; Carr TH; de Bruin EC; Schiavon G; Oliveira M; Turner N
    Ann Oncol; 2019 Jun; 30(6):945-952. PubMed ID: 30860573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.